BezzioCFestaSZerboniGPapiCManesGSaibeniS.A safety evaluation of budesonide MMX for the treatment of ulcerative colitis. Expert Opin Drug Saf. 2018;17:437-444. doi:10.1080/14740338.2018.1442432
2.
DanielssonAPrytzH.Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994;8:585-590.
3.
PeiselerMLiebscherTSebodeMet al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2018;16:260-267.e1. doi:10.1016/j.cgh.2016.12.040
4.
NaranjoCABustoUSellersEMet al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
5.
VattiRRAliFTeuberSChangCGershwinME.Hypersensitivity reactions to corticosteroids. Clin Rev Allergy Immunol. 2014;47:26-37. doi:10.1007/s12016-013-8365-z
